pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,353 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1032Endpoints784BioPharma Dive299BioSpace219Fierce Biotech207onclive165raps78globenewswire health
therapy area
allOncology6093Rare Disease1461Cardiology1094Hematology1029Immunology1009Vaccines918Pulmonology
  • Thermo Fisher sells microbiology biz; Ligand to buy XOMA
    Thermo Fisher Scientific sells microbiology business: Astorg, a European private equity firm, will acquire the unit for $1.075 billion. Thermo Fisher’s microbiology business is part of its specialt…
    Endpoints · 3mo ago↗ source
  • STAT+: An insider reveals the real goals of prior authorization
    Years ago, Archelle Georgiou helped squash prior auths at one of America's biggest health insurers.
    STAT · 3mo ago↗ source
  • Lilly to buy startup Ajax in bid for a better JAK drug
    Worth up to $2.3 billion overall, the deal hands Lilly a drug designed to address the weaknesses of a class of medicines used to treat myelofibrosis and other diseases.
    BioPharma Dive · 3mo ago↗ source
← prev
page 92 of 95
next →
73
fda recalls47
fda medwatch41
fda press28
911
Psychiatry & CNS724
Ophthalmology422
Pain405
Endocrinology & Metabolism384
Infectious Disease361
  • Oruka posts Phase 2 win in psoriasis, hoping to compete with Skyrizi
    Oruka Therapeutics' Phase 2 psoriasis data could mean there's a future challenger to megablockbuster Skyrizi. The company said on Monday that 40 of 63 patients (63.5%) who took an experimental drug…
    Endpoints · 3mo ago↗ source
  • STAT+: Astellas retries XLMTM gene therapy after deaths
    Veradermics' hair loss pill late-stage trial success, FDA fast-tracks reviews for psychedelics, and more biotech news
    STAT · 3mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about a Lilly deal, an Intellia CRISPR rare-disease treatment, and more
    Intellia disclosed that a single dose of its gene editing treatment dramatically reduced swelling attacks in patients with hereditary angioedema
    STAT · 3mo ago↗ source
  • Intellia CRISPR drug succeeds in late-stage study against rare swelling disorder
    The findings position Intellia to bring to market the first “in vivo” gene editing medicine, though the therapy’s commercial potential remains the source of intense investor debate.
    BioPharma Dive · 3mo ago↗ source
  • What’s the true risk for eating disorders with GLP-1s?
    The state of Covid-19 in 2026, a hat to treat depression, and other health news from Morning Rounds
    STAT · 3mo ago↗ source
  • Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitor
    Eli Lilly keeps putting its GLP-1 windfall to use. On Monday, the anti-obesity drugmaker announced its latest deal to expand its pipeline of future drugs, saying it would spend as much as
    Endpoints · 3mo ago↗ source
  • Compass Therapeutics unveils key secondary endpoint results from pivotal biliary tract cancer trial
    A year after it reported a Phase 2/3 success, Compass Therapeutics on Monday revealed further results for its closely watched bispecific antibody in second-line biliary tract cancer. While the inve…
    Endpoints · 3mo ago↗ source
  • Intellia's in vivo CRISPR therapy first to succeed in Phase 3
    An experimental treatment that uses CRISPR to edit genes directly inside the body has just succeeded in a Phase 3 trial — a first for the technology — putting it on track for a potential FDA approv…
    Endpoints · 3mo ago↗ source
  • STAT+: Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trial
    With good results from Intellia, the CRISPR field faces the question: How attractive will the one-and-done approach be to patients and doctors?
    STAT · 3mo ago↗ source
  • Veradermics wins at growing hair with oral Rogaine in first key test as a public company
    Veradermics has succeeded in its first major test as a newly-minted public company. The biotech's form of oral Rogaine cleared the bar in a Phase 2/3 trial in men with mild-to-moderate pattern hair…
    Endpoints · 3mo ago↗ source
  • AI biotech Fathom raises $47M Series A, renames from Atommap
    In the early 2000s, way before AI became a ubiquitous buzzword in biotech, billionaire scientist David Shaw was building supercomputers to study molecules at his eponymous research company. Huafeng…
    Endpoints · 3mo ago↗ source
  • STAT+: Veradermics’ hair loss drug succeeds in late-stage trial
    The company is one of the most advanced players in the hair loss field, which has seen a surge of investor enthusiasm.
    STAT · 3mo ago↗ source
  • STAT+: Oruka’s long-acting psoriasis therapy posts strong results in mid-stage study
    A long-acting injectable treatment for plaque psoriasis helped 63% of patients achieve complete skin clearance in a clinical trial, its maker, Oruka Therapeutics, reported.
    STAT · 3mo ago↗ source
  • STAT+: Zap in a cap: How one neurotech startup is using a hat to treat depression
    FDA approved a request from Motif Neurotech, to start an initial feasibility trial to test a brain implant to treat depression.
    STAT · 3mo ago↗ source
  • NIH-funded research lags in reporting sex differences, new study finds
    Fewer than half of papers published by NIH-funded researchers analyze or report their data by sex, a new study found.
    STAT · 3mo ago↗ source
  • Opinion: I’m a fourth-year med student, but I only learned one historical example of medical racism
    Modern randomized controlled trials often rely on marginalized populations abroad.
    STAT · 3mo ago↗ source
  • Opinion: Patients seeking mental health treatment are not commodities
    Legal agreements that directly shape access to care remain invisible to the very people whose lives they govern.
    STAT · 3mo ago↗ source
  • What happened to Covid?
    The thinking about what risk Covid poses — or doesn't pose — has shifted in recent years. What does it mean for you?
    STAT · 3mo ago↗ source
  • Sun Pharma to buy Organon for $11.75B in major portfolio expansion
    Indian drug giant Sun Pharma has lined up an $11.75 billion acquisition of Organon, a women’s health and biosimilar maker spun out of Merck in 2021. The all-cash deal came in at $14 per share ...
    Endpoints · 3mo ago↗ source
  • Investment in UK biotechs shows early signs of recovery, report says
    After a lull in mid-2025, investment in UK biotechs appears to be picking up, according to data from the UK trade group the BioIndustry Association. In the first quarter of 2026, total equity fundi…
    Endpoints · 3mo ago↗ source
  • STAT+: Doctor, wife of acting U.S. attorney general, appointed to NIH advisory council
    An integrative medicine doctor who is the wife of the acting U.S. attorney general has been named as a member to one of the advisory councils that provides critical funding…
    STAT · 3mo ago↗ source
  • Nancy Cox, a CDC veteran and a stalwart in global flu research, dies at 77
    Nancy Cox, a CDC veteran who for decades was a global leader in influenza research, has died at 77.
    STAT · 3mo ago↗ source